Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observationShaun G. Goodman, Ivan Pećin, Vera Bittner et al.|European Heart Journal - Cardiovascular Pharmacotherapy|2024Cited by 24
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMESPhilippe Gabríel Steg, Nikolaus Marx, Michael Szarek et al.|Circulation|2025Cited by 23